10 Result(s)
within
C Benson
Biomedicine
-
Article
Approach to screening for Familial Adenomatous Polyposis (FAP) in a cohort of 226 patients with Desmoid-type Fibromatosis (DF): experience of a specialist center in the UK
Desmoid-type fibromatosis (DF) are locally infiltrative, non-metastasizing tumours associated with significant morbidity and mortality if located intra-abdominally, retroperitoneally or in head and neck locali...
-
Article
Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study
Since the publication of this paper, the authors noticed an error in Fig. 1. The X-axis on all the figure panels should read ‘Time (years)’, not ‘Time (months)’. The corrected Fig. 1 is shown below.
-
Article
Open AccessAggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response
One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, con...
-
Article
Open AccessRadiation induced angiosarcoma of the breast: outcomes from a retrospective case series
Radiation induced angiosarcoma (RIAS) of the breast is a rare and aggressive complication of radiotherapy. Due to the rarity of this disease, much of the evidence for its management is based on case reports or...
-
Article
Open AccessChemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study
An increasing number and proportion of cancer patients with apparently localised disease are treated with chemotherapy and radiation therapy in contemporary oncology practice. In a pilot study of radiation-ind...
-
Article
Health locus of control and attributions of cause and blame in adjustment to spinal cord injury
The Symptom Checklist 90 Revised (SCL-90-R) was used to assign participants to either a good adjustment group or a poor adjustment group. Group differences were analyzed with χ2, t-tests and correlations on facto...
-
Article
Open AccessA phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and 9 to enter clinical trial. Preclinical studies showed antitumour activity in a broa...
-
Article
Open AccessClinical anticancer drug development: targeting the cyclin-dependent kinases
Cell division involves a cyclical biochemical process composed of several step-wise reactions that have to occur once per cell cycle. Dysregulation of cell division is a hallmark of all cancers. Genetic and ep...
-
Article
Open AccessThe treatment of advanced renal cell cancer with high-dose oral thalidomide
Thalidomide is reported to suppress levels of several cytokines, angiogenic and growth factors including TNF-α, basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and interleukin-...
-
Article
Comparative in vitro activity of A-56268 (TE-031) against gram-positive and gram-negative bacteria andChlamydia trachomatis
The in vitro activity of A-56268 (TE-031) was determined and compared with that of 13 antibiotics against 401 gram-positive and gram-negative bacteria and 11 strains of Chlamydia trachomatis.A-56268 was very act...
